Improves Survival of and Mice During Lethal Infection with .

: is a vegetal species popularly used to treat fungal infections. This study evaluated the anti- effect of extract after lethal infection in larvae and mice. : The chemical profile analysis of a hydroethanolic extract of the leaves of (EHVG) identified 14 compounds.

Controlled Dynamic Microfluidic Culture of Murine, Bovine, and Human Embryos Improves Development: Proof-of-Concept Studies.

Classical preimplantation embryo culture is performed in static fluid environments. Whether a dynamic fluid environment, like the fallopian tube, is beneficial for embryo development remains to be determined across mammalian species. Objectives of these proof-of-concept studies were to determine if controllable dynamic microfluidic culture would enhance preimplantation murine, bovine, and human embryo development compared to static culture.

Type VI secretion systems promote intraspecific competition and host interactions in a bee gut symbiont.

The Type VI Secretion System (T6SS) is a sophisticated mechanism utilized by gram-negative bacteria to deliver toxic effector proteins into target cells, influencing microbial community dynamics and host interactions. In this study, we investigated the role of T6SSs in wkB2, a core bacterial symbiont of the honey bee gut microbiota. We generated single- and double-knockout mutants targeting essential genes ( and ) in both T6SS-1 and T6SS-2 and assessed their colonization and competition capabilities in vivo.

Real-World Efficacy of Biological Therapies in Severe Asthma: A Focus on Small Airways.

: Severe asthma is a challenging condition that often resists traditional treatments and requires high-dose inhaled corticosteroids and other controllers to manage uncontrolled symptoms. Recent advances include the use of biologic agents targeting specific inflammation pathways, which have improved symptom control and quality of life, although their effects on small airways remain less understood. : This prospective observational study, conducted at Tor Vergata University Hospital in Rome from July 2021 to March 2024, aims to evaluate the efficacy of treatments in patients with uncontrolled severe asthma.